Highest-materiality recent filing
Absci reports positive interim Phase 1 data for ABS-201; completes $100M offering
Positive interim Phase 1 data for ABS-201: well tolerated, half-life ≥65 days, supports 2-3 doses/6 months.
Absci prices $100M common stock offering at $7.41/share; Lilly, other investors participate
13,495,277 shares priced at $7.41 each; gross proceeds ~$100M, net ~$93.5M after fees.
No serious adverse events; TEAEs were mild except one moderate headache deemed unrelated to treatment.
Absci completes all SAD cohorts of ABS-201, initiates MAD; Q1 net loss $29.6M
Successfully dosed all four SAD cohorts of ABS-201 Phase 1/2a; well-tolerated with favorable safety.
Absci reports Q4 net loss $29.6M, advances ABS-201 trial, appoints new CMO
Dosed first three cohorts in SAD portion of Phase 1/2a HEADLINE trial for ABS-201; well-tolerated with favorable emerging safety.
Absci appoints Ransi Somaratne as CMO; Chief Innovation Officer Andreas Busch to retire
Ransi Somaratne, formerly SVP Clinical Development at Vertex, appointed CMO effective March 3, 2026.
Absci Reports Q3 2025 Results, Advances ABS-201 and ABS-101 Programs
Reported interim Phase 1 data for ABS-101 (anti-TL1A) showing extended half-life with no serious adverse events.
Absci Q2 2025 net loss $30.6M; raises $64M in July; Almirall collaboration expands
Q2 2025 revenue $0.6M (down from $1.3M YoY); net loss $30.6M vs $24.8M prior year.
Net loss $30.6M in Q2 2025 (vs $24.8M in Q2 2024); revenue $0.6M (vs $1.3M).
Absci prices $50M public offering of 16.67M shares at $3.00 per share
Offering of 16,670,000 shares at $3.00 per share; gross proceeds ~$50M.
Absci starts Phase 1 dosing for ABS-101; Q1 net loss $26.3M, cash into H1 2027
Initiated dosing in first-in-human Phase 1 study of ABS-101 (anti-TL1A); interim data expected H2 2025.
Absci Q4 revenue $0.7M, net loss $29M; pipeline advances and AMD collaboration
Q4 revenue $0.7M (vs $0.3M YoY); net loss $29.0M vs $23.5M.
Revenue $1.7M (up from $0.7M YoY); net loss $27.4M vs $22.0M; cash $127.1M at Sept 30, 2024.
Absci delivered AI-designed antibody sequences to AstraZeneca, fulfilling first milestone under December 2023 collaboration.
Absci Q2 2024: revenue $1.3M, net loss $24.8M; ABS-101 half-life 2-3x; MSK collab
Q2 revenue $1.3M (down from $3.4M YoY); net loss $24.8M vs $41.7M (incl. $21.3M non-cash impairment in prior year).
Absci reports Q1 net loss $22M, cash $161.5M; advances ABS-101 to IND-enabling studies
Q1 2024 revenue $0.9M (down from $1.3M YoY); net loss $22.0M vs $23.4M prior year.
Absci Q4 net loss $23.5M; initiates IND-enabling for ABS-101; AstraZeneca deal up to $247M
FY23 net loss $110.6M, revenue $5.7M flat YoY; Q4 net loss $23.5M.
Absci prices $75.2M public offering of 16.7M shares at $4.50; net proceeds $70.2M
Offering of 16.7M shares at $4.50/share; gross proceeds ~$75.2M; net proceeds ~$70.2M.
Absci reports prelim FY2023 revenue $5.7M, cash $97.7M; proposes public offering
Preliminary Q4 revenue ~$0.3M, FY revenue ~$5.7M; operating expenses $120-122M incl $21.3M goodwill impairment.
Absci announces strategic R&D partnership with PrecisionLife to develop AI-enabled drug pipeline
Partnership combines Absci's generative AI antibody design with PrecisionLife's disease biology to develop up to five drug targets.
Absci announces up to $247M AI antibody collaboration with AstraZeneca for oncology target
Absci to apply its generative AI antibody platform to design an oncology candidate for AstraZeneca.
Absci partners with Almirall (up to $664M deal) and reports Q3 net loss of $22M
Entered AI drug partnership with Almirall for dermatology; up to $664M in milestones plus royalties for two programs.
Mutual separation; effective September 15, 2023, with consulting period through October 15, 2023.
Absci appoints new CFO; Q2 revenue up but net loss widens on $21.3M goodwill impairment
Zach Jonasson, Ph.D. named CFO and CBO effective Aug 31, 2023, replacing retiring CFO Greg Schiffman.
Absci enters into $100M at-the-market equity offering with Cowen
ATM program allows Absci to sell up to $100M of common stock through Cowen as sales agent.
Absci Q1 2023: Net loss $23.4M; cash $144.3M; zero-shot AI breakthrough; new partnerships
Revenue $1.3M (up from $0.8M YoY); net loss narrowed to $23.4M from $29.5M.
Absci Q4 2022 net loss $19.5M; full-year loss $104.9M; cash $164.4M; 10 new Active Programs in 2023
Q4 2022 revenue $1.6M, net loss $19.5M vs $25.2M loss in Q4 2021.
Absci confirms no cash or securities at Silicon Valley Bank
Absci Corporation states it does not hold any deposits or securities at Silicon Valley Bank.
Absci Q3 revenue $2.4M; cash burn guidance improved to ~$105M for 2022
Cash and short-term investments $181.3M at Sep 30, down from $206.0M at Jun 30; operating cash use $19.0M in Q3.
Andreas Busch resigns from Board on Sept 30 to become Chief Innovation Officer effective Oct 4, 2022.
Absci Q2 net loss $28.7M, exceeds Active Program guidance, restructures to extend cash to late-2025
Net loss of $28.7M in Q2 2022, compared to $41.2M loss in Q2 2021.
Absci Q1 net loss $29.5M; cash $226M; signs Merck collaboration worth up to $610M
Net loss of $29.5M in Q1 2022 vs $11.0M in Q1 2021; R&D expense $15.8M, SG&A $10.9M.
Q4 2021 revenue $1.5M, net loss $25.2M vs $4.9M YoY; FY2021 net loss $101.0M vs $14.4M.
On April 25, 2025, Amrit Nagpal notified Absci Corporation (the “Company”) that he would resign from the Company’s Board of Directors and all committees thereof, effective as of April 25, 2025.
On December 5, 2023, the Board of Directors (the “Board”) of Absci Corporation (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Professor Sir Menelas Pangalos to the Board effective January 1, 2024.
On August 16, 2023, Absci Corporation (the “Company”) and Sarah Korman, Ph.D., JD mutually agreed that Dr. Korman’s employment with the Company will end effective as of September 15, 2023
On August 11, 2023, Gregory Schiffman, the Company’s Chief Financial Officer, notified the Company of his decision to retire.
On August 11, 2023, the Company’s Board of Directors appointed Zachariah Jonasson, Ph.D. as the Company’s Chief Financial Officer, Chief Business Officer and Treasurer, effective as of August 31, 2023.
On June 2, 2023, the Board of Directors (the “Board”) of Absci Corporation (the “Company”) appointed Frans van Houten to the Board effective that same date.
On November 1, 2022, the Board of Directors (the “Board”) of Absci Corporation (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dan Rabinovitsj to the Board effective that same date.
effective immediately upon his appointment as the Company's Chief Innovation Officer
he would resign from the Company's Board of Directors
Matthew Weinstock, Ph.D., the Company's Chief Technology Officer, will transition into a consultant role on October 4, 2022.
On September 15, 2022, Absci Corporation (the “Company”) and Nikhil Goel, the Company’s Chief Strategy Officer, agreed that Mr. Goel’s employment with the Company would end effective as of September 20, 2022.
On July 8, 2022, Eli Casdin notified Absci Corporation (the “Company”) that he would resign from the Company’s Board of Directors and all committees thereof, effective as of July 11, 2022.
Max materiality 0.90 · Median 0.65 · Most common event other_material